Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Lenvatinib +/- Comprehensive Local Consolidative Therapy in Oligo-Extrahepatic Metastatic HCC
NCT07537946Phase 3Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Overall Survival up to 60 months. Planned start May 2026; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07537946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537946.